TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29783914

Group type: EXPERIMENTAL
Intervention: Fist Assist® device applied 15 cm proximal to arteriovenous fistula, enabling 60 mmHg of cyclic compression for 6 hours daily for 30 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 46
Study: 27464712

Group type: EXPERIMENTAL
Intervention: Liquid emulsion of coenzyme Q10 (250 mg daily for 1 week)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Solid formulation of coenzyme Q10 (250 mg daily for 1 week)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both formulations (liquid emulsion and solid)
Number of subjects: 6
Study: 25406242

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MeDiet) adherence
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Reduction in carbohydrate intake (≤9.5 g/d)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: MUFA+PUFA/carbohydrates ratio increase
Number of subjects: 521
Study: 23907233

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjugated Estrogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21709611

Group type: EXPERIMENTAL
Intervention: Socially stimulating group intervention
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 235
Study: 19394014

Group type: EXPERIMENTAL
Intervention: FFS (fine-threaded wires with a washer)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tension band wiring
Number of subjects: 24
Study: 16671835

Group type: EXPERIMENTAL
Intervention: Deaf participants (students with hearing loss)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Typical hearing participants (students without hearing loss)
Number of subjects: 62
Study: 15562791

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) for more than 1 year
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non-ADT (control group)
Number of subjects: 49
Study: 11520309

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 9261316

Group type: EXPERIMENTAL
Intervention: Immunochromatography (IC)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Enzyme immunoassay (EIA)
Number of subjects: 130
Study: 8301062

Group type: EXPERIMENTAL
Intervention: Imidazole-salicylate (750 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3329078

Group type: EXPERIMENTAL
Intervention: Collatex vaginal contraceptive sponge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neo Sampoon foaming vaginal contraceptive tablets
Number of subjects: 0
Study: 30772584

Group type: EXPERIMENTAL
Intervention: Doppler Probe Examination (DPE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional Endoscopic Visual Assessment (TEA)
Number of subjects: 100
Study: 28440105

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Doxazosin 8 mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 25467613

Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude manipulation of the cervical spine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive head-movement control
Number of subjects: 10
Study: 24034602

Group type: EXPERIMENTAL
Intervention: Subtotal hysterectomy (SH)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Total hysterectomy (TH)
Number of subjects: 184
Study: 21167795

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate solution
Number of subjects: 156

Group type: COMPARATOR
Intervention: Single sodium phosphate enema
Number of subjects: 156
Study: 18627372

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 9384

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 9384

Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 9384

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 9384

Group type: COMPARATOR
Intervention: Fumaric acid esters
Number of subjects: 9384
Study: 16169681

Group type: EXPERIMENTAL
Intervention: Radiation fraction size 2 Gy (Arm A)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Radiation fraction size 2.25 Gy (Arm B)
Number of subjects: 180
Study: 12664317

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg, 2 times daily for 12 days
Number of subjects: 116

Group type: COMPARATOR
Intervention: Meloxicam 7.5 mg for 12 days
Number of subjects: 116
Study: 10360903

Group type: EXPERIMENTAL
Intervention: Assisted hatching using a piezo-micromanipulator
Number of subjects: 173

Group type: COMPARATOR
Intervention: Nontreated embryos
Number of subjects: 173
Study: 7567393

Group type: EXPERIMENTAL
Intervention: Color-specific method (Red Light Means Stop approach)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional systems
Number of subjects: 43
Study: 1718699

Group type: EXPERIMENTAL
Intervention: Diltiazem and aspirin administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prompt cardiac catheterisation and myocardial revascularisation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise stress testing with 201Tl perfusion scintigraphy
Number of subjects: 0
Study: 7103635

Group type: EXPERIMENTAL
Intervention: Fluoxymesterone (30 mg/day) plus necessary transfusions
Number of subjects: 29

Group type: COMPARATOR
Intervention: Transfusions only
Number of subjects: 29
Study: 29736490

Group type: COMPARATOR
Intervention: 5% sodium fluoride varnish (positive control)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 3% potassium oxalate
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High power diode laser
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Two-step self-etching adhesive
Number of subjects: 19
Study: 27046456

Group type: EXPERIMENTAL
Intervention: PRP + IVB
Number of subjects: 33

Group type: COMPARATOR
Intervention: PRP
Number of subjects: 33
Study: 24495697

Group type: EXPERIMENTAL
Intervention: Priority Mail
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Incentive & Priority Mail
Number of subjects: 976

Group type: COMPARATOR
Intervention: Control
Number of subjects: 976
Study: 22450358

Group type: EXPERIMENTAL
Intervention: Tonic heat pain at 42 °C
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tonic heat pain at 46 °C
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition (no stimulation)
Number of subjects: 20
Study: 20665875

Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paclitaxel‐eluting stent
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Embolic protection devices (EPDs)
Number of subjects: 80
Study: 18534135

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg once a day for up to 28 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once a day for up to 28 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sodium diclofenac 50 mg twice a day for 10 days (Control)
Number of subjects: 75
Study: 15777290

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg kg(‐1) followed by 10 microg.kg(‐1).h(‐1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 microg kg(‐1) followed by 20 microg.kg(‐1).h(‐1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Alfentanil 30 microg kg(‐1) followed by 30 microg.kg(‐1).h(‐1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no alfentanil)
Number of subjects: 31
Study: 12450889

Group type: EXPERIMENTAL
Intervention: Caffeine treatment (870 mg caffeine/d)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Coffee treatment (0.9 L paper-filtered coffee providing approximately 870 mg caffeine/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo treatment (3 placebo capsules)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Coffee treatment (0.45 L coffee)
Number of subjects: 48
Study: 9807846

Group type: EXPERIMENTAL
Intervention: Local infiltration of tenoxicam (10 mg in 10 ml normal saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam (20 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam (10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no preoperative local infiltration or intravenous tenoxicam)
Number of subjects: 60
Study: 7665863

Group type: EXPERIMENTAL
Intervention: 28-week interferon-alpha course
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 52-week interferon-alpha course
Number of subjects: 88
Study: 2611126

Group type: EXPERIMENTAL
Intervention: Clinitar (purified coal tar cream)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1% hydrocortisone cream
Number of subjects: 30
Study: 415880

Group type: EXPERIMENTAL
Intervention: NH4Cl administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: NH4HCO3 ingestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCl acidosis
Number of subjects: 0
Study: 31931160

Group type: EXPERIMENTAL
Intervention: Inhaled Lavandula angustifolia Mill. Essential oil
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 30156312

Group type: EXPERIMENTAL
Intervention: Firocoxib (0.3 mg/kg, i.v. loading dose; 0.1 mg/kg, i.v., q24h)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Flunixin meglumine (1.1 mg/kg, i.v., q12h)
Number of subjects: 56
Study: 28479288

Group type: EXPERIMENTAL
Intervention: Concurrent Foley bulb and oxytocin
Number of subjects: 128

Group type: COMPARATOR
Intervention: Oxytocin alone
Number of subjects: 128
Study: 26542513

Group type: EXPERIMENTAL
Intervention: Prasugrel pretreatment (30 mg loading dose)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Timing of CABG <2.98 days
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Timing of CABG ≥2.98 and <6.95 days
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Timing of CABG ≥6.95 days
Number of subjects: 314
Study: 23510310

Group type: EXPERIMENTAL
Intervention: Any cataract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nuclear cataract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortical cataract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posterior subcapsular cataract (PSC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age-related factors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sex-related factors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Race-related factors
Number of subjects: 0
Study: 22710541

Group type: EXPERIMENTAL
Intervention: 5% KOH solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.05% tretinoin cream
Number of subjects: 50
Study: 19266185

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Y + H (Yohimbine + Hydrocortisone)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17264849

Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg b.i.d.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 15230906

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen and 1000 mg acetaminophen
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 11350098

Group type: EXPERIMENTAL
Intervention: Interval hypoxic training (three to four periods of 7 min progressive hypoxia in 1 h, each day for 14 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (breathing into a spirometer)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Interval hypoxic training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 9164365

Group type: EXPERIMENTAL
Intervention: Acaricide (esdepallethin and piperonyl butoxide - 'Acardust') combined with environmental control
Number of subjects: 46

Group type: COMPARATOR
Intervention: Continuous house dust mite avoidance measures
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo acaricide treatment combined with avoidance measures
Number of subjects: 46
Study: 8778156

Group type: EXPERIMENTAL
Intervention: Salbutamol (400 micrograms)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Broxaterol (400 micrograms)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Exercise + Broxaterol
Number of subjects: 11
Study: 1975487

Group type: EXPERIMENTAL
Intervention: Zidovudine, 500 mg orally every 4 hours for 12 weeks, combined with six peripheral blood lymphocyte infusions and bone marrow transplantation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Zidovudine, 100 mg every 4 hours for 12 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 81244

Group type: EXPERIMENTAL
Intervention: Doxantrazole
Number of subjects: 13
Study: 31611625

Group type: EXPERIMENTAL
Intervention: Novel therapeutic approaches
Number of subjects: 3894

Group type: EXPERIMENTAL
Intervention: Age-related factors
Number of subjects: 3894

Group type: EXPERIMENTAL
Intervention: Performance status, international staging score, and molecular risk
Number of subjects: 3894

Group type: EXPERIMENTAL
Intervention: Molecular events
Number of subjects: 3894

Group type: EXPERIMENTAL
Intervention: Performance status
Number of subjects: 3894
Study: 30642296

Group type: EXPERIMENTAL
Intervention: PlasmaJet Surgical Device
Number of subjects: 330

Group type: COMPARATOR
Intervention: Standard surgical instruments combined with electrocoagulation (Control)
Number of subjects: 330
Study: 28381202

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 24997634

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet (MSD)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 49
Study: 22268972

Group type: EXPERIMENTAL
Intervention: 5-weekly group mantram intervention
Number of subjects: 32
Study: 19892778

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6500
Study: 18687149

Group type: EXPERIMENTAL
Intervention: Peer-delivered telephone support with DVD education
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Nurse-delivered telephone counselling with DVD education
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210
Study: 15854171

Group type: EXPERIMENTAL
Intervention: Ipocol (2.4 g daily for 8 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Asacol (2.4 g daily for 8 weeks)
Number of subjects: 88
Study: 14521276

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) treatment applied in the region with the highest theta/alpha ratio, triggering a sound when the ratio fell below a threshold value, 20 half-hour sessions at a rate of 2 per week.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Noncontingent reinforcement (Control group).
Number of subjects: 10
Study: 10383532

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 7593419

Group type: EXPERIMENTAL
Intervention: Carbenoxolone (100 mg every 8 h for 7 days)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 7
Study: 2182032

Group type: EXPERIMENTAL
Intervention: 2-dose insulin regimen (mainly intermediate acting insulin before breakfast and dinner)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4-dose insulin regimen (regular insulin preprandially with intermediate acting insulin at bedtime)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2-dose insulin regimen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4-dose insulin regimen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2-dose insulin regimen and 4-dose insulin regimen
Number of subjects: 10
Study: 396655

Group type: EXPERIMENTAL
Intervention: LS 519 (75 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: LS 519 (150 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Carbenoxolone (300 mg/day)
Number of subjects: 64
Study: 31937907

Group type: COMPARATOR
Intervention: Continuous energy restriction (1000 kcal/day for women and 1200 kcal/day for men)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Week-on-week-off energy restriction (alternating between energy restriction and habitual diet)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 5:2 energy restriction (500 kcal/day for women and 600 kcal/day for men on modified fast days)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 109
Study: 30611977

Group type: EXPERIMENTAL
Intervention: Smartphone application consisting of personalized feedback, risk assessment and self-monitoring
Number of subjects: 977
Study: 28514205

Group type: EXPERIMENTAL
Intervention: CRT+endostar
Number of subjects: 0

Group type: COMPARATOR
Intervention: CRT only
Number of subjects: 0
Study: 25514821

Group type: EXPERIMENTAL
Intervention: Shoulder-strengthening program (6 months, 3 times a week)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Comparable handball training program (no specific upper-body strength training)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Shoulder-strengthening program
Number of subjects: 109
Study: 24226711

Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg/d for 3 days)
Number of subjects: 200
Study: 21121988

Group type: EXPERIMENTAL
Intervention: 500 ppm NaF
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 500 ppm AmF
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 500 ppm MFP
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 500 ppm MFP and xylitol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonfluoridated dentifrice
Number of subjects: 50
Study: 19213225

Group type: EXPERIMENTAL
Intervention: Rapid absorbing gut suture
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tissue adhesive (2-octylethylcyanoacrylate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 8
Study: 17556414

Group type: EXPERIMENTAL
Intervention: Lead-chelation therapy with calcium disodium EDTA
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Lead-chelation therapy
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Repeated chelation therapy
Number of subjects: 116
Study: 14764176

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators (ICDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (mainly amiodarone)
Number of subjects: 0
Study: 11250998

Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy
Number of subjects: 1772

Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 1772

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1772
Study: 9337166

Group type: EXPERIMENTAL
Intervention: Subcutaneous port insertion
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Ball-valve effect as a primary complication
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Port-related venous thrombosis as a subsequent complication
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Ball-valve effect as a risk factor for venous thrombosis
Number of subjects: 119
Study: 8202898

Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg with flurbiprofen 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2438319

Group type: EXPERIMENTAL
Intervention: Inosiplex (isoprinosine) therapy for 20 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo for 20 weeks
Number of subjects: 25
Study: 29979479

Group type: EXPERIMENTAL
Intervention: Recreational football
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (non-training)
Number of subjects: 42
Study: 27809793

Group type: EXPERIMENTAL
Intervention: 4 Pillars™ Practice Transformation Program
Number of subjects: 70549

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70549
Study: 23983269

Group type: EXPERIMENTAL
Intervention: Volume-oriented incentive spirometry (VIS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Flow-oriented incentive spirometry (FIS)
Number of subjects: 16
Study: 24237190

Group type: EXPERIMENTAL
Intervention: Chromium supplementation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chromium plus sertraline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chromium alone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 21168715

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 25

Group type: COMPARATOR
Intervention: CNI discontinuation
Number of subjects: 25
Study: 18977831

Group type: EXPERIMENTAL
Intervention: Palmar plate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dorsal Pi-plate
Number of subjects: 30
Study: 16648225

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 14714846

Group type: EXPERIMENTAL
Intervention: Simulated post-soldering procedure
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Multiple firing
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 11049917

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.2 mg/kg IV bolus, followed by infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cisatracurium with propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg IV, followed by infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60